Modeling of the maximum combination effects between glucocorticoid receptor agonists and EPZ-6438 in <i>EZH2</i> mutant and wild-type germinal center B cell lymphoma.

<p>Combinations of EPZ-6438 with Prednisolone (A, C) or Dexamethasone (B, D) in WSU-DLCL2 <i>EZH2</i> mutant (A, B) and DOHH2 <i>EZH2</i> wild-type (C, D) GCB lymphoma cell lines. The data presented in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0111840#pone-0111840-g002" target="_blank">Fig. 2</a> were analyzed such that a maximal possible shift in potency was calculated (1/α, see supplementary text in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0111840#pone.0111840.s002" target="_blank">S1 File</a>). A, B) Potency of EPZ-6438 was increased by a maximum 24-fold with Prednisolone and 30-fold with Dexamethasone in <i>EZH2</i> mutant WSU-DLCL2 cells. C, D) EPZ-6438 shows no anti-proliferative effect as a single agent in DOHH2 <i>EZH2</i> wild-type cells, therefore the potency shift of Prednisolone or Dexamethasone was measured. Potency of Prednisolone was increased a maximum of 9.5-fold with addition of EPZ-6438, and potency of Dexamethasone was increased a maximum of 8.3-fold with addition of EPZ-6438 in DOHH2 cells.